Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Medicare's open wallet comes with a ledger: build the paper trail before volume

Payment at the full fee schedule rate is a win for Lucid, but the same week's $127m fraud plea shows the scrutiny every new reimbursement stream will face. Evidence discipline is a pricing asset.

15 Nov 2026 · CompePharma editorial

Two Medicare stories, one lesson

Last week's material offered two Medicare headlines that look unrelated. Lucid Diagnostics said Medicare is paying EsoGuard claims at $1,938.01 per test, the full fee schedule rate, and reported record October volume. Separately, the US Justice Department said Daniel Lee, a Queens adult day care director, pleaded guilty to conspiracy to commit health care fraud and money laundering in a $127m scheme involving unnecessary prescription drugs and adult day care services never delivered.

Nothing connects the two, and I am not suggesting otherwise. But they describe the same system from opposite sides. Medicare is willing to pay a premium price for a new product, and it is also a payer that is repeatedly defrauded and knows it. Any company that builds a revenue line on Medicare has to expect to be judged in that context.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →